Ability of B-Type Natriuretic Peptide in Predicting Postoperative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting
Objectives: Atrial fibrillation (AF) is still the most frequent rhythm disturbance after coronary artery surgery. Our aim was to evaluate the predictive value of preoperative brain natriuretic peptide (BNP) levels for determining postoperative new-onset AF in patients undergoing isolated first-time coronary artery bypass grafting (CABG) using cardiopulmonary bypass (CPB).
Methods: We recruited 144 consecutive patients (51 women and 93 men) who underwent isolated CABG. Preoperative and postoperative data were collected. Preoperative BNP levels were measured the day before surgery.
Results: The median preoperative BNP level was 68 pg/mL. Postoperative AF occurred in 36 (25%) of the patients. Univariate analyses showed that both advanced age and median preoperative BNP levels were associated with postoperative AF (63.9 ± 8 years versus 57.3 ± 9.8 years, P < .001; 226 pg/mL versus 65.2 pg/mL, P <.001). Both variables remained independent predictors of postoperative AF after multivariate logistic regression analyses. For advanced age, the odds ratio was 1.074 (95% confidence interval [CI], 1.019-1.131; P = .008); for preoperative BNP level, the odds ratio was 1.004 (95% CI, 1.001-1.006; P = .002). A receiver operating characteristic (ROC) curve demonstrated that preoperative BNP level was a predictor of postoperative AF, with an area under the ROC curve of 0.750. A cutoff value of 135 pg/mL for AF demonstrated a 72.2% sensitivity, a 71.2% specificity, a 45.6% positive predictive value, a 88.5% negative predictive value, and a 71.5% accuracy for predicting postoperative AF.
Conclusions: Elevated preoperative BNP levels and advanced age together are significant predictors for the development of postoperative AF in patients undergoing isolated CABG with CPB.
Aranki SF, Shaw DP, Adams DH, et al. 1996. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation 94:390-7.nBettencourt P, Ferreira S, Azevedo A, Ferreira A. 2002. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am J Med 113:215-9.nCheng V, Kazanagra R, Garcia A, et al. 2001. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37:386-91.nCosgrave J, Foley JB, McGovern E, et al. 2006. Brain natriuretic peptide elevation and the development of atrial fibrillation following coronary artery bypass surgery. Interact Cardiovasc Thorac Surg 5:111-4.nCreswell LL, Schuessler RB, Rosenbloom M, Cox JL. 1993. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 56:539-49.nDao Q, Krishnaswamy P, Kazanegra R, et al. 2001. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 37:379-85.nDorge H, Schoendube FA, Schoberer M, Stellbrink C, Voss M, Messmer BJ. 2000. Intraoperative amiodarone as prophylaxis against atrial fibrillation after coronary operations. Ann Thorac Surg 69:1358-62.nDucceschi V, D'Andrea A, Liccardo B, et al. 1999. Perioperative clinical predictors of atrial fibrillation occurrence following coronary artery bypass surgery. Eur J Cardiothorac Surg 16:435-9.nFerguson TB Jr, Smith LS, Smith PK, Damiano RJ, Cox JL. 1987. Electrical activity in the heart during hyperkalemic hypothermic cardioplegic arrest: site of origin and relationship to specialized conduction tissue. Ann Thorac Surg 43:373-9.nFrancis GS, Benedict C, Johnstone DE, et al. 1990. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82:1724-9.nGottlieb SS, Kukin ML, Ahern D, Packer M. 1989. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 13:1534-9.nHakala T, Hedman A, Turpeinen A, Kettunen R, Vuolteenaho O, Hippeläinen M. 2002. Prediction of atrial fibrillation after coronary artery bypass grafting by measuring atrial peptide levels and preoperative atrial dimensions. Eur J Cardiothorac Surg 22:939-43.nHutfless R, Kazanegra R, Madani M, et al. 2004. Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. J Am Coll Cardiol 43:1873-9.nKalman JM, Munawar M, Howes LG, et al. 1995. Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Ann Thorac Surg 60:1709-15.nKitzman DW, Edwards WD. 1990. Age-related changes in the anatomy of the normal heart. J Gerontol 45:33-9.nLeitch JW, Thomson D, Baird DK, Harris PJ. 1990. The importance of age as a predictor of atrial fibrillation and flutter after coronary artery bypass grafting. J Thorac Cardiovasc Surg 100:338-42.nMaeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. 1998. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135:825-32.nMaisel A. 2001. B-type natriuretic peptide levels: diagnostic and therapeutic potential. Cardiovasc Toxicol 1:159-64.nMaisel AS, Krishnaswamy P, Nowak RM, et al, for the Breathing Not Properly Multinational Study Investigators. 2002. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161-7.nMathew JP, Parks R, Savino JS, et al. 1996. Atrial fibrillation following coronary artery bypass graft surgery: predictors, outcomes, and resource utilization. MultiCenter Study of Perioperative Ischemia Research Group. JAMA 276:300-6.nMcCullough PA, Nowak RM, McCord J, et al. 2002. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106:416-22.nMorita E, Yasue H, Yoshimura M, et al. 1993. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88:82-91.nMoulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. 1996. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 111:1037-46.nNozaki N, Yamaguchi S, Shirakabe M, Nakamura H, Tomoike H. 1997. Soluble tumor necrosis factor receptors are elevated in relation to severity of congestive heart failure. Jpn Circ J 61:657-64.nOmland T, Persson A, Ng L, et al. 2002. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106:2913-8.nPfisterer ME, Klöter-Weber UC, Huber M, et al. 1997. Prevention of supraventricular tachyarrhythmias after open heart operation by low-dose sotalol: a prospective, double-blind, randomized, placebo-controlled study. Ann Thorac Surg 64:1113-9.nRichards AM, Nicholls MG, Espiner EA, et al. 2003. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107:2786-92.nRousou JA, Meeran MK, Engelman RM, Breyer RH, Lemeshow S. 1985. Does the type of venous drainage or cardioplegia affect postoperative conduction and atrial arrhythmias? Circulation 72:II 259-63.nTurk T, Ata Y, Ay D, et al. 2008. Plasma brain natriuretic peptide after isolated on-pump coronary artery bypass grafting: prediction of postoperative adverse outcomes. Heart Surg Forum 11:84-9.nTurk T, Vural H, Eris C, Ata Y, Yavuz S. 2007. Atrial fibrillation after off-pump coronary artery surgery: a prospective, matched study. J Int Med Res 35:134-42.nWazni OM, Martin DO, Marrouche NF, et al. 2004. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 110:124-7.nWendelboe Nielsen O, Kirk V, Bay M, Boesgaard S, Nielsen H. 2004. Value of N-terminal pro brain natriuretic peptide in the elderly: data from the prospective Copenhagen Hospital Heart Failure study (CHHF). Eur J Heart Fail 6:275-9.nWhite HD, Antman EM, Glynn MA, et al. 1984. Efficacy and safety of timolol for prevention of supraventricular tachyarrhythmias after coronary artery bypass surgery. Circulation 70:479-84.nYasue H, Yoshimura M, Sumida H, et al. 1994. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90:195-203.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).